The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has achieved a milestone associated with its Phase 2/3 ...

Novavax also emphasized its strategic partnerships, notably with Sanofi, and the authorization of its updated COVID-19 vaccine formula across major markets, including the U.S. and Europe.